You are here: Industry Insights > Cancer

News List

Zenfold Ventures takes equity stake in Esperer Onco Nutrition expresspharma
April 16, 2020
Over the next two years, Esperer Onco Nutrition plans to have more technical collaborations with international technical authorities to expand its research and product portfolio.
Tango Therapeutics banks $60M to push synthetic lethality drug fiercebiotech
April 13, 2020
Many cancer patients have benefited from targeted therapies that switch off cancer-driving oncogenes, but others, whose disease is driven by the loss of tumor-suppressing genes.
GenScript ProBio, Eutilex Enter Cancer Collaboration contractpharma
April 10, 2020
Partner on plasmid and virus process development and manufacturing for CAR-T programs.
China-based Biotech Laekna Acquires Global Rights to Develop and Commercialize anti-PD-L1 Antibody oncozine
March 30, 2020
Laekna will receive exclusive global rights to FAZ053, an investigational anti-PD-L1 antibody being developed by Novartis for the treatment of patients with advanced forms of cancer.
Astellas, CytomX form T-cell engaging cancer antibodies partnership pharmatimes
March 27, 2020
Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer.
Mass cytometry could reveal best cancer drug regimens for clinical trials europeanpharmaceuticalreview
March 25, 2020
Researchers have developed a new technology that could provide real-time analysis of patient samples during clinical trials to reveal the best cancer treatment regimens.
Lynparza Granted Orphan Drug Designation in Japan for Pancreatic Cancer americanpharmaceuticalreview
March 23, 2020
AstraZeneca announced Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer.
NICE fails to recommend pembrolizumab in final draft guidance europeanpharmaceuticalreview
March 17, 2020
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
EMA begins safety review of ifosfamide cancer medicines europeanpharmaceuticalreview
March 17, 2020
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
Statins starve cancer cells to death worldpharmanews
March 16, 2020
More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels. Now, in experiments with human cells in the laboratory ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page